Navigation Links
Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th
Date:6/21/2009

ts) for those that received standard chemotherapy.

"It is gratifying that we are seeing more patients convert to complete remission after the initial assessment period with pixantrone compared to other agents. These additional late responders are likely to have a positive impact on analyses of progression free and overall survival and will be provided to the U.S. Food and Drug Administration during the 120-day update," stated James A. Bianco, M.D., Chief Executive Officer of CTI. "We plan to request priority review of the NDA from the FDA as we believe that pixantrone would provide patients and physicians with a compelling new option in treating this disease."

Review of Pixantrone Clinical Studies in Indolent non-Hodgkin's lymphoma

Additionally, data from two previously reported clinical trials investigating pixantrone combined with other agents in indolent NHL is being reviewed. In one trial, PIX 302, patients that received pixantrone plus rituximab achieved higher CR and ORR rates, (CR=35% (7 of 20 patients); ORR=75% (15 of 20 patients)) as well as a longer TTP (13.2 months) than those who only received rituximab alone (CR=11% (2 of 18 patients); ORR=33% (6 of 18 patients); TTP=8.1 months) in relapsed/refractory indolent NHL. In a separate study, AZA I06, pixantrone and the FPD-R regimen achieved high response rates (CR/CRu=70% (19 of 27 patients); ORR=89% (24 of 27 patients) in relapsed/refractory indolent NHL, nearly all of whom had received aggressive first-line therapy with CHOP-R.

The Pan Pacific Lymphoma Conference poster is available at http://www.celltherapeutics.com/investor_updates.

About the PIX 301 EXTEND Trial

The PIX 301 EXTEND trial was a phase III single-agent trial of pixantrone for patients with relapsed or refractory, aggressive NHL who received two or more
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
2. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
3. Micromets BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkins Lymphoma
4. SARS Vaccine Achieves Neutralizing Responses in First U.S. Human Trial
5. Vical Pandemic Influenza Vaccines Achieve T-Cell Responses and Cross-Clade Reactivity in Humans
6. Use it or Lose it: A New Theory About Preserving Erectile Function After Prostate Surgery
7. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
8. Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept)
9. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
10. AHF Seeks White House Clarification After Press Room Flap Over CDCs HIV Numbers
11. New Implantable Lenses Can Reduce the Need for Glasses After Cataract Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014 Arbor Pharmaceuticals, LLC. - ... Global Markets Direct,s, ,Arbor Pharmaceuticals, LLC. - Product ... the Arbor Pharmaceuticals, LLC.,s pharmaceutical research and development ... the current therapeutic developmental pipeline of Arbor Pharmaceuticals, ... therapeutics assessment by drug target, mechanism of action ...
(Date:9/30/2014)... BURLINGTON, Mass. , Sept. 30, 2014  Decision ... (PV) devices in Brazil , ... and China (BRIC) will see ... techniques are increasingly favored over surgical procedures. Although revenues ... care resources, reimbursement challenges, prolonged device approval times and ...
(Date:9/30/2014)... , Sept. 30, 2014  According to their ... of cancer clinical trials is going through a ... and the work of the current clinical trial ... of ,next generation, clinical trials, which will ultimately ... The company has been recognized by ...
Breaking Medicine Technology:Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 2Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 3Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 2Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 3Small Denver Company Pharmatech driving a large revolution in how cancer clinical trials are managed 2
... , April 27, 2010 Shire plc (LSE: ... it has received a Paragraph IV Notice Letter from Anchen,Pharmaceuticals, ... Application ("ANDA") for a generic version of Shire,s 1 mg, ... tablets, INTUNIV(TM).,Shire had previously reported in March 2010 ...
... April 27 For a second consecutive year, following the ... Auto Thefts) is cautioning Michigan drivers, and now auto dealers ... theft-related crimes.   , , ... increased vehicle security features, and the continuing success of Michigan ...
Cached Medicine Technology:Shire Receives INTUNIV(TM) Paragraph IV Notice Letter From Anchen 2Shire Receives INTUNIV(TM) Paragraph IV Notice Letter From Anchen 3H.E.A.T. Warns Drivers, Auto Dealers of Continuing Trend in Unconventional Auto Crimes 2H.E.A.T. Warns Drivers, Auto Dealers of Continuing Trend in Unconventional Auto Crimes 3
(Date:10/1/2014)... Despite a policy focus on expanding access to ... population continues to have significant dental disease. In ... the American Dental Association , researchers from Tufts ... of Dental Medicine report on the first large-scale ... provided by caregivers to adults with developmental disabilities. ...
(Date:10/1/2014)... CA (PRWEB) October 01, 2014 Bedros ... Fit Body Boot Camp fitness boot camps, he’s also ... personal training , with sold out business summits, a ... as marketing consultant to a recent Spike TV reality ... says that now is the time for personal trainers ...
(Date:10/1/2014)... Farmington Company today announced it has ... visual identity helping brokers, consultants and companies to ... create greater benefit communication synergies. They unveiled a ... customers to better leverage Farmington Company’s industry-tested experience ... the rebrand is the refreshed tagline: For the ...
(Date:10/1/2014)... Jupiter, FL (PRWEB) October 01, 2014 ... Begley, Jr., scheduled to broadcast on Monday, October 20, ... In this episode, Innovations will go behind the scenes ... prevention programs. This segment will explore the practical help ... young adults, which teaches the warning signs of abuse, ...
(Date:10/1/2014)... 2014 On Sept. 9, Chapín Coffee ... the Martha Stewart American Made Awards (MSAMAs), an annual ... country in the fields of crafts, design, food and ... a finalist in the MSAMAs, which celebrates entrepreneurs and ... improving local communities and changing the way we shop, ...
Breaking Medicine News(10 mins):Health News:To improve oral health of adults with developmental disabilities, support caregivers 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 3Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 3Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Innovations to Explore Breakthroughs in Health and Wellness in Upcoming Episode Airing Monday, October 20, 2014 via Discovery Channel 2Health News:Chicago Coffee Start-up Makes a Big Impact, Earns National Recognition 2
... at the University of Iowa Roy J. and Lucille A. ... (PET) technology can help // doctors gauge the response of ... and co-author Bruce Cheson, M.D., of the Lombardi Comprehensive Cancer ... usage of PET n gauging the response of the tumor ...
... loan of $ 260 M to Kenya by the World ... be in rough weather as it has been delayed due ... ,The corruption charges are against the Kenyan government, the ... ,According to the Kenyan Ministry of Health in February 2005 ...
... Biocon, an Indian biotechnology company will raise its investments ... destination for clinical development of drugs. Biocon is reported ... with life sciences organizations in Scotland. There are more ... than 26,500 people. Scotland will serve to fill the ...
... Won Jang of the Department of Internal Medicine at the ... that administering an antiviral drug would help prevent hepatitis ... treatment of cancer. ,In hepatocellular carcinoma (HCC), patients ... a result of chemotherapy. Hepatocellular carcinoma or liver cancer is ...
... has found prominence again, for the wrong reasons. Blaming the ... // held the post of Chief Scientific Officer at ... the risks of MMR triple vaccine adequately, despite a lurking fear ... if this doubt is proved, it could turn out to be ...
... implantation of stem cells into the pancreas of type 2 ... endogenous insulin. // In addition, it has been associated with ... decrease in blood sugar levels. ,If approved, this ... diabetics from receiving insulin or drugs to stimulate the production ...
Cached Medicine News:Health News:Hepatitis B Relapse In Cancer Chemotherapy Can Be Avoided By Antiviral Drug 2
... testing your blood glucose regularly, you want ... possible. Conventional spring-loaded lancet systems often penetrate ... cause painful dilation or tearing of skin ... a precise, linear action that provides greater ...
... Focus from Thermo Labsystems was designed specifically ... Advanced features such as the new fast ... on microvolumes help to define this as ... The new interchangeable handle plate offers a ...
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,410-0) or contact custom...
... models cover the range from 2ul to 5000ul. ... Volume lock design prevents inadvertent volume change. ... Whole pipette is autoclavable at 121C(250F). ... polypropylene. Suitable for one-handed operation. Auto ...
Medicine Products: